ArticleSurgery today2025
Clinical outcomes of pancrelipase administration after pancreaticoduodenectomy.
Article in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposesThis study investigated the risk factors for nonalcoholic fatty liver disease (NAFLD) after pancreaticoduodenectomy (PD) and the need for prophylactic pancrelipase administration in all patients.
methodsThis study included 180 patients who underwent PD between 2007 and 2023. Persistent liver dysfunction and severe diarrhea after PD are indications for pancrelipase administration. We retrospectively investigated the relationship between clinical variables and the postoperative development of NAFLD and the use of pancrelipase after PD.
resultsA total of 36 (20%) patients developed NAFLD after PD. Age < 75 years old, female sex, pancreatic cancer, persistent liver dysfunction, and pancrelipase administration were identified as risk factors for the development of NAFLD in the univariate analysis, and age < 75 years old, female sex, and persistent liver dysfunction were identified as risk factors in the multivariate analysis. In total, 42 (23%) patients were administered pancrelipase, of whom 14 (33%) developed NAFLD. In contrast, among the 138 patients not administered pancrelipase, 116 (84%) did not develop NAFLD (p = 0.014).
conclusionsAge < 75 years old, female sex, and persistent liver dysfunction were significantly associated with NAFLD development after PD. Many patients do not develop NAFLD after PD, even without the administration of pancrelipase. Prophylactic pancrelipase may not be necessary for all patients after PD.
Indexed as
Identifiers
40500466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.